Evidence map›Paper›PMID 35210430›Full record

ArticleSchizophrenia (Heidelberg, Germany)2022

Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics.

Christoph U Correll, Amber Martin, Charmi Patel, Carmela Benson, Rebecca Goulding, Jennifer Kern-Sliwa, Kruti Joshi, Emma Schiller, Edward Kim

Abstract read
In one paragraph

Article in Schizophrenia (Heidelberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 13 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 13 syntheses or guidelines pooled it.

  1. Pooled it
  2. The Australian and New Zealand journal of psychiatry · 2026
    Guideline
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Guideline
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Article

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Christoph U CorrellThe Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, NY, USA. CCorrell@northwell.edu.ORCID http://orcid.org/0000-0002-7254-5646
Amber MartinEvidera, Waltham, MA, USA.
Charmi PatelJanssen Scientific Affairs, LLC, Titusville, NJ, USA.
Carmela BensonJanssen Scientific Affairs, LLC, Titusville, NJ, USA.
Rebecca GouldingGoulding HEOR Consulting Inc., Vancouver, BC, Canada.
Jennifer Kern-SliwaJanssen Scientific Affairs, LLC, Titusville, NJ, USA.
Kruti JoshiJanssen Scientific Affairs, LLC, Titusville, NJ, USA.
Emma SchillerEvidera, Waltham, MA, USA.
Edward KimBiohaven Pharmaceuticals, New Haven, CT, USA.ORCID http://orcid.org/0000-0001-8247-6675

Funding

Janssen Pharmaceuticals (Janssen Pharmaceuticals, Inc.) noneJanssen Pharmaceuticals (Janssen Pharmaceuticals, Inc.) None
6 · The paper itself

Abstract

Clinical practice guidelines (CPGs) translate evidence into recommendations to improve patient care and outcomes. To provide an overview of schizophrenia CPGs, we conducted a systematic literature review of English-language CPGs and synthesized current recommendations for the acute and maintenance management with antipsychotics. Searches for schizophrenia CPGs were conducted in MEDLINE/Embase from 1/1/2004-12/19/2019 and in guideline websites until 06/01/2020. Of 19 CPGs, 17 (89.5%) commented on first-episode schizophrenia (FES), with all recommending antipsychotic monotherapy, but without agreement on preferred antipsychotic. Of 18 CPGs commenting on maintenance therapy, 10 (55.6%) made no recommendations on the appropriate maximum duration of maintenance therapy, noting instead individualization of care. Eighteen (94.7%) CPGs commented on long-acting injectable antipsychotics (LAIs), mainly in cases of nonadherence (77.8%), maintenance care (72.2%), or patient preference (66.7%), with 5 (27.8%) CPGs recommending LAIs for FES. For treatment-resistant schizophrenia, 15/15 CPGs recommended clozapine. Only 7/19 (38.8%) CPGs included a treatment algorithm.

Identifiers

PMID35210430
PMCPMC8873492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.